Stock TCRX TSCAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Real-time Estimate Cboe BZX
Other stock markets
 11:24:30 2024-04-29 am EDT 		5-day change 1st Jan Change
7.63 USD +4.23% Intraday chart for TScan Therapeutics, Inc. +6.60% +30.19%
Apr. 19 TScan Therapeutics Closes $150.1 Million Securities Offering MT
Apr. 17 TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TScan Therapeutics, Inc. Provides Clinical Pipeline Update and Highlights Near-Term Priorities
TScan Therapeutics, Inc. Announces Executive Changes
TScan Therapeutics Files $300 Million Mixed-Securities Shelf
TScan Therapeutics Q4 Net Loss Narrows, Revenue Increases
TScan Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
TScan Therapeutics Names Jason Amello as Finance Chief
Tscan Therapeutics, Inc. Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 At the 65Th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors
TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
TScan Therapeutics Receives FDA Approval for TSC-203-A0201's Investigational New Drug Application
TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Tscan Therapeutics, Inc. Announces Management Appointments
TScan Therapeutics CFO to Step Down in July
TScan Therapeutics, Inc. Announces Board Changes
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Sector Update: Health Care
TScan Therapeutics Says Investigational New Drug Application for Solid Tumor Treatment Received US FDA Clearance
TScan Therapeutics Expects $140.6 Million From Share Sale to Fund Expenses into 2026; Shares Jump Premarket
Top Midday Decliners
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TCRX Stock
  4. News TScan Therapeutics, Inc.
  5. Other languages